NYSE:EW - Edwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences shares split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly issued shares were payable to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences declared that its board has approved a stock buyback program on Thursday, December 7th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board believes its shares are undervalued.

Edwards Lifesciences Corp (NYSE:EW) released its quarterly earnings data on Wednesday, October, 23rd. The medical research company reported $1.41 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.22 by $0.19. The medical research company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The company's revenue was up 20.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.07 earnings per share. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, December, 5th. The company provided earnings per share (EPS) guidance of $6.05-6.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.98. The company issued revenue guidance of $4.5-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.

18 analysts have issued twelve-month price objectives for Edwards Lifesciences' stock. Their forecasts range from $159.00 to $285.00. On average, they anticipate Edwards Lifesciences' share price to reach $237.65 in the next year. This suggests that the stock has a possible downside of 0.6%. View Analyst Price Targets for Edwards Lifesciences.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

Media coverage about EW stock has been trending negative this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Edwards Lifesciences earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Edwards Lifesciences.

Edwards Lifesciences saw a decrease in short interest in October. As of October 31st, there was short interest totalling 2,320,000 shares, a decrease of 15.9% from the September 30th total of 2,760,000 shares. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is currently 2.1 days. Currently, 1.1% of the company's shares are sold short. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Home Depot (HD), Visa (V), UnitedHealth Group (UNH), Mastercard (MA), Gilead Sciences (GILD), QUALCOMM (QCOM) and CVS Health (CVS).

Edwards Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.22%), Massachusetts Financial Services Co. MA (0.72%), Disciplined Growth Investors Inc. MN (0.68%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), CIBC Private Wealth Group LLC (0.35%) and Parametric Portfolio Associates LLC (0.32%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Disciplined Growth Investors Inc. MN, Assenagon Asset Management S.A., Orbimed Advisors LLC, Calamos Advisors LLC, First Trust Advisors LP, Squarepoint Ops LLC and Country Trust Bank. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State of New Jersey Common Pension Fund D, Sumitomo Mitsui Trust Holdings Inc., Columbus Circle Investors, Penserra Capital Management LLC, Point72 Asset Management L.P., Massachusetts Financial Services Co. MA and State of Tennessee Treasury Department. View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $238.98.

Edwards Lifesciences has a market capitalization of $49.84 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.View Additional Information About Edwards Lifesciences.

The official website for Edwards Lifesciences is http://www.edwards.com/.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]